Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Rui Zhang, Samantha D Clark, Beibei Guo, Tianyi Zhang, Duane Jeansonne, Samithamby J Jeyaseelan, Joseph Francis & Weishan Huang. (2023) Challenges in the combination of radiotherapy and immunotherapy for breast cancer. Expert Review of Anticancer Therapy 23:4, pages 375-383.
Read now
Read now
Li Li, Weiqiang Shi & Juying Zhou. (2021) Effect of CMNa combined with radiotherapy on the tumor immune microenvironment of mouse cervical cancer cell transplantation tumor model. Bioengineered 12:1, pages 1066-1077.
Read now
Read now
Xuqi Sun, Dandan Hu, Zhoutian Yang, Zheng Liu, Juncheng Wang, Jinbin Chen, Li Xu, Zhongguo Zhou, Minshan Chen & Yaojun Zhang. (2020) Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy. Journal of Hepatocellular Carcinoma 7, pages 337-345.
Read now
Read now
Olav Dahl, Mette Pernille Myklebust, Jon Espen Dale, Otilia Leon, Eva Serup-Hansen, Anders Jakobsen, Per Pfeiffer, Inger Marie Løes, Frank Pfeffer, Karen-Lise Garm Spindler, Marianne Grønlie Guren, Bengt Glimelius & Anders Johnsson. (2020) Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. Acta Oncologica 59:9, pages 1016-1023.
Read now
Read now
Caroline Lum, Hans Prenen, Amy Body, Marissa Lam & Eva Segelov. (2020) A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape. Expert Review of Gastroenterology & Hepatology 14:8, pages 665-680.
Read now
Read now
Andrea Casadei-Gardini, Francesco Montagnani, Chiara Casadei, Francesca Arcadipane, Kalliopi Andrikou, Deborah Aloi, Alessandra Anna Prete, Maria Giulia Zampino, Antonella Argentiero, Giuseppe Pugliese, Stefania Martini, Giuseppe Carlo Iorio, Mario Scartozzi, Massimiliano Mistrangelo, Lorenzo Fornaro, Paola Cassoni, Giorgia Marisi, Veronica Dell’Acqua, Paola Simona Ravenda, Sara Lonardi, Nicola Silvestris, Berardino De Bari, Umberto Ricardi, Stefano Cascinu & Pierfrancesco Franco. (2019) Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier). Cancer Management and Research 11, pages 3631-3642.
Read now
Read now
Olav Dahl, Jon Espen Dale & Marianne Brydøy. (2019) Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment. Acta Oncologica 58:1, pages 9-20.
Read now
Read now
Yu-Jie Zhao, Wei-Peng Sun, Jian-Hong Peng, Yu-Xiang Deng, Yu-Jing Fang, Jun Huang, Hui-Zhong Zhang, De-Sen Wan, Jun-Zhong Lin & Zhi-Zhong Pan. (2018) Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Management and Research 10, pages 1-11.
Read now
Read now
Annika Antonsson, Lani Knight, Benedict J. Panizza, Sandro V. Porceddu, Sarah Emmett & David C. Whiteman. (2018) HPV-16 viral load in oropharyngeal squamous cell carcinoma using digital PCR. Acta Oto-Laryngologica 138:9, pages 843-847.
Read now
Read now
Articles from other publishers (62)
Yutaro Ikeuchi, Masanori Someya, Tomokazu Hasegawa, Masato Saito, Shoh Mafune, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Hironari Dehari, Kazuhiro Ogi, Takanori Sasaki, Yoshihiko Hirohashi, Toshihiko Torigoe, Naoki Hirokawa, Akihiro Miyazaki & Koh-ichi Sakata. (2023) Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer. Medical Molecular Morphology 56:4, pages 288-296.
Crossref
Crossref
Laxmi Upadhyay, Michelle Hartzell, Aparna R. Parikh, Matthew R. Strickland, Samuel Klempner & Midhun Malla. (2023) Recent Advances in the Management of Anal Cancer. Healthcare 11:23, pages 3010.
Crossref
Crossref
Soledad Iseas, Diego Prost, Sarah Bouchereau, Mariano Golubicki, Juan Robbio, Ana Oviedo, Mariana Coraglio, Mirta Kujaruk, Guillermo Méndez, Marcela Carballido, Enrique Roca, Louis Gros, Vincent De Parades, Nabil Baba-Hamed, Julien Adam, Martín Carlos Abba & Eric Raymond. (2023) Prognostic Factors of Long-Term Outcomes after Primary Chemo-Radiotherapy in Non-Metastatic Anal Squamous Cell Carcinoma: An International Bicentric Cohort. Biomedicines 11:3, pages 791.
Crossref
Crossref
Alessandra A. Prete, Paolo Manca, Marco Messina, Vincenzo Formica, Giovanni L. Frassineti, Maria G. Zampino, Domenico C. Corsi, Corrado Orciuolo, Michele Prisciandaro, Francesca Bergamo, Valentina Angerilli, Mario Scartozzi, Mariaelena Casagrande, Gianluca Masi, Monica Ronzoni, Federica Morano, Valentina Vettore, Roberta Salmaso, Cosimo Rasola, Giulia Maddalena, Paola del Bianco, Massimo Milione, Chiara Cremolini, Matteo Fassan, Filippo Pietrantonio & Sara Lonardi. (2023) Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study. European Journal of Cancer 182, pages 87-97.
Crossref
Crossref
Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Masashi Idogawa, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito & Koh-ichi Sakata. (2022) Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy. Medical Molecular Morphology 56:1, pages 38-45.
Crossref
Crossref
Mengchao An, Wenkang Wang, Jie Zhang, Brian G. Till, Lingdi Zhao, Hao Huang, Yonghao Yang, Tiepeng Li, Lu Han, Xiaojie Zhang, Peng Qin, Yunjian Wang, Min Zhang, Hong Cui, Quanli Gao & Zibing Wang. (2022) Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy. Cancer Immunology, Immunotherapy 72:2, pages 385-395.
Crossref
Crossref
Daniel R. Principe, Jose L. Cataneo, Kaytlin E. Timbers, Regina M. Koch, Klara Valyi-Nagy, Anders Mellgren, Ajay Rana & Gerald Gantt. (2022) Leukocyte subtyping predicts for treatment failure and poor survival in anal squamous cell carcinoma. BMC Cancer 22:1.
Crossref
Crossref
Stelios Theophanous, Robert Samuel, John Lilley, Ann Henry, David Sebag-Montefiore, Alexandra Gilbert & Ane L. Appelt. (2022) Prognostic factors for patients with anal cancer treated with conformal radiotherapy—a systematic review. BMC Cancer 22:1.
Crossref
Crossref
Pierfrancesco Franco, Annamaria Porreca, Giovanna Mantello, Francesca Valvo, Lucrezia Gasparini, Najla Slim, Stefania Manfrida, Francesca De Felice, Marianna A. Gerardi, Stefano Vagge, Marco Krengli, Elisa Palazzari, Mattia Falchetto Osti, Alessandra Gonnelli, Gianpiero Catalano, Patrizia Pittoni, Giovani B. Ivaldi, Marco Lupattelli, Maria Elena Rosetto, Rita Marina Niespolo, Alessandra Guido, Oreste Durante, Gabriella Macchia, Fernando Munoz, Badr El Khouzai, Maria Rosaria Lucido, Francesca Arcadipane, Andrea Casadei Gardini, Rolando Maria D'Angelillo, Maria Antonietta Gambacorta, Domenico Genovesi, Marta Di Nicola & Luciana Caravatta. (2022) External validation of a composite bio-humoral index in anal cancer patients undergoing concurrent chemoradiation. Radiotherapy and Oncology 177, pages 9-15.
Crossref
Crossref
Rita Saúde-Conde, Alessandro Parisi, Emilio Francesco Giunta, Michel Meyers & Francesco Sclafani. (2022) The emerging role of immunotherapy in the treatment of anal cancer. Current Opinion in Pharmacology 67, pages 102309.
Crossref
Crossref
Ranadip Mandal, Monika Raab, Franz Rödel, Andrea Krämer, Izabela Kostova, Samuel Peña-Llopis, Gioele Medici, Björn Häupl, Thomas Oellerich, Khayal Gasimli, Mourad Sanhaji, Sven Becker & Klaus Strebhardt. (2022) The non-apoptotic function of Caspase-8 in negatively regulating the CDK9-mediated Ser2 phosphorylation of RNA polymerase II in cervical cancer. Cellular and Molecular Life Sciences 79:12.
Crossref
Crossref
Angela MY. Chan, Gloria Roldan Urgoiti, Will Jiang, Sandra Lee, Elizabeth Kornaga, Peter Mathen, Rosanna Yeung, Emeka K. Enwere, Alan Box, Mie Konno, Martin Koebel, Kurian Joseph & Corinne M. Doll. (2022) The prognostic impact of PD-L1 and CD8 expression in anal cancer patients treated with chemoradiotherapy. Frontiers in Oncology 12.
Crossref
Crossref
Luca Mastracci, Federica Grillo, Paola Parente, Irene Gullo, Michela Campora, Valentina Angerilli, Chiara Rossi, Maria Luisa Sacramento, Gianmaria Pennelli, Alessandro Vanoli & Matteo Fassan. (2022) PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. Pathologica 114:5, pages 352-364.
Crossref
Crossref
Ashley L. Monsrud, Vaidehi Avadhani, Marina B. Mosunjac, Lisa Flowers & Uma Krishnamurti. (2022) Programmed Death Ligand-1 Expression Is Associated With Poorer Survival in Anal Squamous Cell Carcinoma. Archives of Pathology & Laboratory Medicine 146:9, pages 1094-1101.
Crossref
Crossref
Karina Cereceda, Nicolas Bravo, Roddy Jorquera, Roxana González-Stegmaier & Franz Villarroel-Espíndola. (2022) Simultaneous and Spatially-Resolved Analysis of T-Lymphocytes, Macrophages and PD-L1 Immune Checkpoint in Rare Cancers. Cancers 14:11, pages 2815.
Crossref
Crossref
Luca Hladek, Katrin Bankov, Jens von der Grün, Natalie Filmann, Melanie Demes, Stefan Vallo, Peter J. Wild & Ria Winkelmann. (2022) Tumor-associated immune cell infiltrate density in penile squamous cell carcinomas. Virchows Archiv 480:6, pages 1159-1169.
Crossref
Crossref
Masanori Someya, Yuki Fukushima, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito & Koh-ichi Sakata. (2022) Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy. Japanese Journal of Radiology 40:5, pages 458-465.
Crossref
Crossref
Iske F. van Luijk, Sharissa M. Smith, Maria C. Marte Ojeda, Arlene L. Oei, Gemma G. Kenter & Ekaterina S. Jordanova. (2022) A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment. Journal of Clinical Medicine 11:9, pages 2277.
Crossref
Crossref
Davide Ciardiello, Luigi Pio Guerrera, Brigida Anna Maiorano, Paola Parente, Tiziana Pia Latiano, Massimo Di Maio, Fortunato Ciardiello, Teresa Troiani, Erika Martinelli & Evaristo Maiello. (2022) Immunotherapy in advanced anal cancer: Is the beginning of a new era?. Cancer Treatment Reviews 105, pages 102373.
Crossref
Crossref
D. Martin, T. Schreckenbach, P. Ziegler, N. Filmann, G. Kalinauskaite, I. Tinhofer, V. Budach, C. Gani, D. Zips, T. Schimek-Jasch, H. Schäfer, A.L. Grosu, E. Thomas, M. Krause, H. Dapper, S. Combs, C. Hoffmann, M. Stuschke, F. Walter, C. Belka, I. Kurth, W.W Hadiwikarta, M. Baumann, C. Rödel & E. Fokas. (2022) Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: A multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology 167, pages 233-238.
Crossref
Crossref
Marianne Grønlie Guren, David Sebag-Montefiore, Pierfrancesco Franco, Anders Johnsson, Eva Segelov, Eric Deutsch, Sheela Rao, Karen-Lise Garm Spindler & Dirk Arnold. (2021) Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. Clinical Colorectal Cancer 20:4, pages 279-287.
Crossref
Crossref
Haoru Dong, Xinhua Shu, Qiang Xu, Chen Zhu, Andreas M. Kaufmann, Zhi-Ming Zheng, Andreas E. Albers & Xu Qian. (2021) Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care. Virologica Sinica 36:6, pages 1284-1302.
Crossref
Crossref
Patricia Martin-Romano, Julien Adam, Jean-Yves Scoazec, Sébastien Gouy, Antonin Levy, Capucine Baldini, Stéphane Champiat, Jean-Charles Soria, Christophe Massard, Aurélien Marabelle, Eric Deutsch & Antoine Hollebecque. (2021) Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?. Frontiers in Immunology 12.
Crossref
Crossref
Theresa Obermueller, Joris Hautekiet, Maria P. Busto, Dries Reynders, Liliana Belgioia, Annemieke Cats, Duncan C. Gilbert, Stefan A. Koerber, Sabine Mai, Didier Meulendijks, Franz Rödel, Ho-Young Yhim, Svetlana Hetjens, Christel Weiß, Christina L. Rasmussen, Aivara Urbute, Freija Verdoodt, Susanne K. Kjaer, Miriam Reuschenbach, Els Goetghebeur, Magnus von Knebel Doeberitz, Marc Arbyn & Elena-Sophie Prigge. (2021) Prognostic value of high-risk human papillomavirus DNA and p16INK4a immunohistochemistry in patients with anal cancer: An individual patient data meta-analysis. European Journal of Cancer 157, pages 165-178.
Crossref
Crossref
William Tyler Turchan & Stanley L. Liauw. (2021) Chemoradiation for Anal Cancer: Clinical Outcomes and Strategies to Optimize the Therapeutic Ratio According to HPV Status. Seminars in Radiation Oncology 31:4, pages 349-360.
Crossref
Crossref
Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Masakazu Hori, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Yoshihisa Matsumoto & Koh-ichi Sakata. (2021) Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy. Medical Molecular Morphology 54:3, pages 245-252.
Crossref
Crossref
Daniel Martin, Claus Rödel & Emmanouil Fokas. (2021) Innovative Konzepte in der Behandlung des AnalkarzinomsInnovative concepts in the treatment of anal carcinoma. coloproctology 43:3, pages 217-222.
Crossref
Crossref
Mojun Zhu, Zhaohui Jin & Joleen M. Hubbard. (2021) Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers 13:4, pages 651.
Crossref
Crossref
Kathrin Gennen, Lukas Käsmann, Julian Taugner, Chukwuka Eze, Monika Karin, Olarn Roengvoraphoj, Jens Neumann, Amanda Tufman, Michael Orth, Simone Reu, Claus Belka & Farkhad Manapov. (2020) Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiation Oncology 15:1.
Crossref
Crossref
Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Yu Takada, Masakazu Hori, Katsutoshi Miura, Mio Kitagawa, Toshio Gocho, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito & Koh-ichi Sakata. (2020) Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy. Japanese Journal of Clinical Oncology 50:11, pages 1290-1297.
Crossref
Crossref
Daniel Martin, Claus Rödel & Emmanouil Fokas. (2020) RADIANCE – Radiochemotherapie mit oder ohne Durvalumab in der Behandlung des Analkarzinoms: eine randomisierte, multizentrische Phase-II-StudieRADIANCE—chemoradiotherapy with or without durvalumab in the treatment of anal cancer: a randomized, multicenter phase II study. Forum 35:5, pages 415-417.
Crossref
Crossref
Margot Bucau, Nathalie Gault, Nanthara Sritharan, Emy Valette, Charlotte Charpentier, Francine Walker, Anne Couvelard & Laurent Abramowitz. (2020) PD-1/PD-L1 expression in anal squamous intraepithelial lesions. Oncotarget 11:39, pages 3582-3589.
Crossref
Crossref
Anja Wessely, Markus V. Heppt, Claudia Kammerbauer, Theresa Steeb, Thomas Kirchner, Michael J. Flaig, Lars E. French, Carola Berking, Elisa Schmoeckel & Markus Reinholz. (2020) Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma. Cancers 12:9, pages 2516.
Crossref
Crossref
Takaaki Tsuchiya, Masanori Someya, Yu Takada, Tomokazu Hasegawa, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Masakazu Hori, Kensei Nakata, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito & Koh-ichi Sakata. (2020) Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Strahlentherapie und Onkologie 196:8, pages 725-735.
Crossref
Crossref
Daniel Martin, Panagiotis Balermpas, Johannes Gollrad, Christian Weiß, Chiara Valentini, Martin Stuschke, Henning Schäfer, Christoph Henkenberens, Jürgen Debus, David Krug, Thomas Kuhnt, Thomas Brunner, Tilman Bostel, Rita Engenhart-Cabillic, Ursula Nestle, Stephanie E. Combs, Claus Belka, Matthias Hautmann, Guido Hildebrandt, Cihan Gani, Bülent Polat, Claus Rödel & Emmanouil Fokas. (2020) RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. Clinical and Translational Radiation Oncology 23, pages 43-49.
Crossref
Crossref
Aivara Urbute, Christina Louise Rasmussen, Federica Belmonte, Theresa Obermueller, Elena-Sophie Prigge, Marc Arbyn, Freija Verdoodt & Susanne K. Kjaer. (2020) Prognostic Significance of HPV DNA and p16INK4a in Anal Cancer: A Systematic Review and Meta-Analysis. Cancer Epidemiology, Biomarkers & Prevention 29:4, pages 703-710.
Crossref
Crossref
Daniel Martin, Claus Rödel & Emmanouil Fokas. (2020) Radiochemotherapie des AnalkarzinomsChemoradiotherapy for anal cancer. Der Onkologe 26:4, pages 339-347.
Crossref
Crossref
Masahiro Kagabu, Takayuki Nagasawa, Chie Sato, Yasuko Fukagawa, Hanae Kawamura, Hidetoshi Tomabechi, Shuji Takemoto, Tadahiro Shoji & Tsukasa Baba. (2020) Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions. International Journal of Molecular Sciences 21:7, pages 2335.
Crossref
Crossref
Luc Dewit, Annemieke Cats & Geerard Beets. 2020. Squamous Cell Carcinoma - Hallmark and Treatment Modalities. Squamous Cell Carcinoma - Hallmark and Treatment Modalities.
Synat Keam, Suki Gill, Martin A Ebert, Anna K Nowak & Alistair M Cook. (2020) Enhancing the efficacy of immunotherapy using radiotherapy. Clinical & Translational Immunology 9:9.
Crossref
Crossref
Clemens Grassberger, Susannah G. Ellsworth, Moses Q. Wilks, Florence K. Keane & Jay S. Loeffler. (2019) Assessing the interactions between radiotherapy and antitumour immunity. Nature Reviews Clinical Oncology 16:12, pages 729-745.
Crossref
Crossref
I. Parwaiz, T.A. MacCabe, M.G. Thomas & D.E. Messenger. (2019) A Systematic Review and Meta-Analysis of Prognostic Biomarkers in Anal Squamous Cell Carcinoma Treated With Primary Chemoradiotherapy. Clinical Oncology 31:12, pages e1-e13.
Crossref
Crossref
Daniel Martin, Franz Rödel, Panagiotis Balermpas, Ria Winkelmann, Emmanouil Fokas & Claus Rödel. (2019) C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy. Frontiers in Oncology 9.
Crossref
Crossref
Bahir H. Chamseddin, Eunice E. Lee, Jiwoong Kim, Xiaowei Zhan, Rong Yang, Kathleen M. Murphy, Cheryl Lewis, Gregory A. Hosler, Suntrea T. Hammer & Richard C. Wang. (2019)
Assessment of circularized E7 RNA, GLUT1, and PD-L1 in anal squamous cell carcinoma
. Oncotarget 10:57, pages 5958-5969.
Crossref
Crossref
Masahiro Kagabu, Takayuki Nagasawa, Daisuke Fukagawa, Hidetoshi Tomabechi, Saiya Sato, Tadahiro Shoji & Tsukasa Baba. (2019) Immunotherapy for Uterine Cervical Cancer. Healthcare 7:3, pages 108.
Crossref
Crossref
Devarati Mitra, Nora K. Horick, Diane G. Brackett, Kent W. Mouw, Jason L. Hornick, Soldano Ferrone, Theodore S. Hong, Harvey Mamon, Jeffrey W. Clark, Aparna R. Parikh, Jill N. Allen, David P. Ryan, David T. Ting, Vikram Deshpande & Jennifer Y. Wo. (2019) High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. The Oncologist 24:6, pages e275-e283.
Crossref
Crossref
D. Martin, C. Rödel & E. Fokas. (2019) Chemoradiotherapy for anal cancer: are we as good as we think?Radiochemotherapie für das Analkarzinom: Sind wir so gut, wie wir denken?. Strahlentherapie und Onkologie 195:5, pages 369-373.
Crossref
Crossref
Yuncong Liu, Li Wu, Ruizhan Tong, Feiyue Yang, Limei Yin, Mengqian Li, Liting You, Jianxin Xue & You Lu. (2019) PD-1/PD-L1 Inhibitors in Cervical Cancer. Frontiers in Pharmacology 10.
Crossref
Crossref
Franz Rödel, Daniel Martin, Panagiotis Balermpas, Ulrike Wieland, Ria Winkelmann, Thorsten Riekmann, Stephan Falk, Claus Rödel & Emmanouil Fokas. (2019) Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1871:1, pages 126-137.
Crossref
Crossref
Paulo C. Soares, Eliana S. Abdelhay, Luiz Claudio S. Thuler, Bruno Moreira Soares, Samia Demachki, Gessica Valéria Rocha Ferro, Paulo P. Assumpção, Leticia Martins Lamarão, Luis Felipe Ribeiro Pinto & Rommel Mario Rodríguez Burbano. (2018) HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma. BMC Gastroenterology 18:1.
Crossref
Crossref
D. Peiffert, A.S. Baumann, A.A. Serre, V. Vendrely, N. Rouard, J.C. Faivre & G. Vogin. (2018) Cancer du canal anal : à l’ère de la radiothérapie conformationnelle avec modulation d’intensité, questions en suspens. Cancer/Radiothérapie 22:6-7, pages 509-514.
Crossref
Crossref
Daniel Martin, Claus Rödel & Emmanouil Fokas. (2018) Nivolumab für das vorbehandelte metastasierte Analkarzinom. Gastro-News 5:4, pages 19-20.
Crossref
Crossref
Daniel Martin, Claus Rödel & Emmanouil Fokas. (2018) Nivolumab für das vorbehandelte metastasierte Analkarzinom. InFo Onkologie 21:4, pages 30-31.
Crossref
Crossref
Daniel Martin, Panagiotis Balermpas, Ria Winkelmann, Franz Rödel, Claus Rödel & Emmanouil Fokas. (2018) Anal squamous cell carcinoma – State of the art management and future perspectives. Cancer Treatment Reviews 65, pages 11-21.
Crossref
Crossref
J.P. Nesseler, D. Schaue, W.H. McBride & P. Nickers. (2018) Biomarqueurs inflammatoires et immunologiques de réponse à la radiothérapie. Cancer/Radiothérapie 22:2, pages 180-192.
Crossref
Crossref
Daniel Martin, Claus Rödel & Emmanouil Fokas. (2018) Nivolumab für das vorbehandelte metastasierte AnalkarzinomNivolumab for pretreated metastatic anal cancer. Strahlentherapie und Onkologie 194:4, pages 356-357.
Crossref
Crossref
A. Casadei Gardini, A. Passardi, L. Fornaro, P. Rosetti, M. Valgiusti, S. Ruscelli, M. Monti, C. Casadei, F. Pagan & G.L. Frassineti. (2018) Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy. Critical Reviews in Oncology/Hematology 123, pages 52-56.
Crossref
Crossref
Franz Rödel, Kerstin Steinhäuser, Nina-Naomi Kreis, Alexandra Friemel, Daniel Martin, Ulrike Wieland, Margret Rave-Fränk, Panagiotis Balermpas, Emmanouil Fokas, Frank Louwen, Claus Rödel & Juping Yuan. (2018) Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. Radiotherapy and Oncology 126:2, pages 214-221.
Crossref
Crossref
Maria Gonzalez-Cao, Niki Karachaliou, Mariacarmela Santarpia, Santiago Viteri, Andreas Meyerhans & Rafael Rosell. (2018) Activation of viral defense signaling in cancer. Therapeutic Advances in Medical Oncology 10, pages 175883591879310.
Crossref
Crossref
Daniel Martin, Franz Rödel, Ria Winkelmann, Panagiotis Balermpas, Claus Rödel & Emmanouil Fokas. (2017) Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer. Frontiers in Immunology 8.
Crossref
Crossref
Daniel Martin, Franz Rödel, Panagiotis Balermpas, Claus Rödel & Emmanouil Fokas. (2017) The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1868:1, pages 221-230.
Crossref
Crossref
Daniel Martin, Claus Rödel & Emmanouil Fokas. (2017) Wie lange sollte bis zur Beurteilung des Therapieansprechens nach Radiochemotherapie des Analkarzinoms gewartet werden?How long should we wait upon completion of chemoradiotherapy before assessment of tumor response in anal cancer?. Strahlentherapie und Onkologie 193:7, pages 593-594.
Crossref
Crossref